Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Sandoz

  • News

Executive Summary

Completes purchase of 1.98 mil. shares of newly-issued SyStemix stock at $56 per share. The purchase is in addition to the $280.8 mil. Sandoz will pay for 60% of the stem cell and megakaryocyte company and was part of the original acquisition agreement ("The Pink Sheet" Dec. 23, p. 1). Sandoz also names six members to the SyStemix board of directors: Sandoz Pharma chairman Max Link, PhD; corporate R&D head Stefan Guttmann; Vice Chairman and CEO of Sandoz Corp. Daniel Wagniere; Sandoz Research Institute President Robert Levy, MD; SRI Senior VP-Preclinical Research Jurg Meier, PhD; and the CEO of Sandoz' Austrian Research Institute Peter Dukor, MD.

Table

View full table

Tags:
Latest Headlines

US FDA Wants Advice About Advisory Committees: Try Having Some?

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

Industry Calls For Caution Over EMA Supply Chain Recommendations

Industry Slates Decision To Exempt Parallel Importers From New Danish Stockpile Rules

See All
UsernamePublicRestriction

Register

PS020463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By